Pfizer (PFE) Operating Expenses (2009 - 2026)

Pfizer (PFE) has 18 years of Operating Expenses data on file, last reported at $5.5 billion in Q1 2026.

• Operating Expenses for Q1 2026 came in at $5.5 billion, down 6.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.4 billion (up 29.83% YoY), and the FY2025 annual result was $25.8 billion, down 6.38% from the prior year.
• Operating Expenses eased to $5.5 billion in Q1 2026 per PFE's latest filing, from $8.1 billion in the prior quarter.
• Over five years, Operating Expenses peaked at $9.0 billion in Q4 2023 and troughed at $5.1 billion in Q2 2022.
• A 5-year average of $6.4 billion and a median of $6.1 billion in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses grew 19.64% in 2024, then fell 22.54% in 2025.
• A 5-year view of Operating Expenses shows it stood at $6.3 billion in 2022, then surged by 43.37% to $9.0 billion in 2023, then tumbled by 31.47% to $6.2 billion in 2024, then soared by 32.15% to $8.1 billion in 2025, then slumped by 32.38% to $5.5 billion in 2026.
• Business Quant data shows PFE's Operating Expenses at $5.5 billion in Q1 2026, $8.1 billion in Q4 2025, and $6.0 billion in Q3 2025.